JW Pharmaceutical Corporation (KRX:001060)
South Korea flag South Korea · Delayed Price · Currency is KRW
27,850
+450 (1.64%)
Last updated: Aug 31, 2026, 2:36 PM KST

JW Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
820,862775,298719,376748,527684,351606,585
Other Revenue
-0-0-0-0--
820,862775,298719,376748,527684,351606,585
Revenue Growth
10.50%7.77%-3.89%9.38%12.82%10.82%
Cost of Revenue
432,641415,984395,878412,984396,397372,209
Gross Profit
388,220359,314323,498335,542287,955234,376
Selling, General & Admin
231,813222,622210,610204,728182,652171,220
Research & Development
43,84645,44736,23733,67133,73619,884
Operating Expenses
280,404271,437240,766238,911227,464203,528
Operating Income
107,81787,87782,73396,63160,49030,848
Interest Expense
-4,424-4,424-10,033-12,562-9,387-7,337
Interest & Investment Income
3,3383,3384,9626,3225,8141,981
Earnings From Equity Investments
2,2282,2591,387621.06-955.41-1,149
Currency Exchange Gain (Loss)
-618.56-618.561,087-1,817-2,300-925.96
Other Non Operating Income (Expenses)
5,433-1,1262,253-36,1025,425-1,191
EBT Excluding Unusual Items
113,77487,30582,39053,09559,08822,227
Gain (Loss) on Sale of Investments
1,5781,578790.92,830-8,908-646.8
Gain (Loss) on Sale of Assets
-46.76-46.76464.91-1,0883.28-1,048
Asset Writedown
---1,476--4,821-
Other Unusual Items
--249.74---
Pretax Income
115,30588,83682,42054,83645,36220,533
Income Tax Expense
14,02427,32517,37916,40615,50921,974
Earnings From Continuing Operations
101,28161,51165,04038,43029,853-1,441
Minority Interest in Earnings
----1,4242,039473.6
Net Income
101,28161,51165,04037,00631,892-967.85
Preferred Dividends & Other Adjustments
863.58863.58----
Net Income to Common
100,41760,64865,04037,00631,892-967.85
Net Income Growth
87.61%-6.75%75.75%16.04%--
Shares Outstanding (Basic)
232325242323
Shares Outstanding (Diluted)
232325242323
Shares Change
-10.27%-7.88%3.34%2.49%0.07%-0.05%
EPS (Basic)
4453.472676.462644.001554.671373.14-41.70
EPS (Diluted)
4453.472676.462644.001554.671373.14-41.70
EPS Growth
109.08%1.23%70.07%13.22%--

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
122,80684,62571,07959,87146,84510,657
Free Cash Flow Per Share
5446.383734.592889.492515.252016.97459.20
Gross Margin
47.29%46.34%44.97%44.83%42.08%38.64%
Operating Margin
13.13%11.34%11.50%12.91%8.84%5.08%
Profit Margin
12.23%7.82%9.04%4.94%4.66%-0.16%
Free Cash Flow Margin
14.96%10.91%9.88%8.00%6.84%1.76%
EBITDA
127,308106,624101,834119,20677,32746,960
EBITDA Margin
15.51%13.75%14.16%15.93%11.30%7.74%
D&A For EBITDA
19,49218,74819,10122,57516,83616,112
EBIT
107,81787,87782,73396,63160,49030,848
EBIT Margin
13.13%11.34%11.50%12.91%8.84%5.08%
Effective Tax Rate
12.16%30.76%21.09%29.92%34.19%107.02%
Advertising Expenses
-22,69124,25222,69022,67318,416